Trial Profile
Phase I trial of GTP-004 in healthy volunteers
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 29 Mar 2018
Price :
$35
*
At a glance
- Drugs Ondansetron/pyridostigmine (Primary) ; Pyridostigmine
- Indications Myasthenia gravis
- Focus Adverse reactions; Proof of concept
- 26 Mar 2018 Results presented in a GT Biopharma media release.
- 09 Jan 2018 Status changed from recruiting to active, no longer recruiting, according to a GT Biopharma media release.
- 09 Jan 2018 According to a GT Biopharma media release, dosing of patients has been completed.